Takeda pays $35 million for Colo. vaccine developer

05/8/2013 | Denver Post, The

Takeda Pharmaceutical, through Takeda America Holdings, agreed to acquire Inviragen for $35 million in cash plus $215 million in potential milestone fees contingent on the progress of the firm's infectious-disease vaccines. Inviragen is developing vaccines for dengue as well as hand, foot and mouth disease.

View Full Article in:

Denver Post, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC